If you have been reading about NR1D2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Agarose is a preferred matrix for work with proteins and nucleic acids as it has a broad range of physical, chemical and thermal stability, and its lower degree of chemical complexity also makes it less likely to interact with biomolecules. Agarose is most commonly used as the medium for analytical scale electrophoretic separation in agarose gel electrophoresis. Gels made from purified agarose have a relatively large pore size, making them useful for separation of large molecules, such as proteins and protein complexes >200 kilodaltons, as well as DNA fragments >100 basepairs. Agarose is also used widely for a number of other applications, for example immunodiffusion and immunoelectrophoresis, as the agarose fibers can function as anchor for immunocomplexes.
== Chemistry literature == Scientific literature Scientific journal Academic journal List of important publications in chemistry List of scientific journals in chemistry List of science magazines Scientific American
The Virginia producer Elysia Crampton's debut album is only four songs long, but it represents a monumental undertaking. [They have] described it as an exploration of Virginia's history as well as a meditation on brownness, on being Latina, and as a kind of geology. [Their] epiphanies feel hard-won, and they shine all the more brightly for it. Crampton released their second album, Elysia Crampton Presents: Demon City, on July 22, 2016. It was a collaboration with friends/peers including Houston producer Rabit, Danish producer Why Be, London producer Lexxi, and Alabama producer Chino Amobi. Music review website Tiny Mix Tapes gave the album a 4.5 out of 5, while Pitchfork said: "Demon City, Virginia producer Elysia Crampton's follow-up to [their] sumptuous debut American Drift, is a wonder of concision and represents another massive leap forward in [their] growth," of the album.
Sources: en.wikipedia.org
The other settings were available to block out interference, but did so by also blocking some of the signal which reduced the overall sensitivity of the system. The output of the mixer was sent to the Y-axis deflection plates in a specially designed high-quality CRT. For reasons not well explained in the literature, this was arranged to deflect the beam downward with increasing signal. When combined with the X-axis signal from the time base generator, echoes received from distant objects caused the display to produce blips along the display. By measuring the centre point of the blip against a mechanical scale along the top of the display, the range to the target could be determined. This measurement was later aided by the addition of the calibrator unit or strobe, which caused additional sharp blips to be drawn every 10 miles (16 km) along the display. The markers were fed from the same electronic signals as the time base, so it was always properly calibrated.
=== Polonnaruwa === On 29 December 2012 a green fireball was observed in Polonnaruwa, Sri Lanka. It disintegrated into fragments that fell to the Earth near the villages of Aralaganwila and Dimbulagala and in a rice field near Dalukkane. Rock samples were submitted to the Medical Research Institute of the Ministry of Health in Colombo. The rocks were sent to the University of Cardiff in Wales for analysis, where Chandra Wickramasinghe's team analyzed them and claimed that they contained extraterrestrial diatoms. From January to March 2013, five papers were published in the fringe Journal of Cosmology outlining various results from teams in the United Kingdom, United States and Germany. However, independent experts in meteoritics stated that the object analyzed by Wickramasinghe's team was of terrestrial origin, a fulgurite created by lightning strikes on Earth. Experts in diatoms complemented the statement, saying that the organisms found in the rock represented a wide range of extant terrestrial taxa, confirming their earthly origin. Wickramasinghe and collaborators responded, using X-ray diffraction, oxygen isotope analysis, and scanning electron microscope observations, in a March 2013 paper asserting that the rocks they found were indeed meteorites, instead of being created by lightning strikes on Earth as stated by scientists from the University of Peradeniya. However, these claims were also criticised for not providing evidence that the rocks were actually meteorites.
=== Plasma processing === In this technique, paper is first rendered hydrophobic using a hydrophobizing agent such as AKD or fluorocarbon plasma polymerization, and then O2 plasma etching with a mask is used to create hydrophilic patterns in the paper. One benefit of plasma based processes is that the complex designs and functionalities such as fully and semi-enclsoed channels, on-off flow switches, and fluid flow control channels can be incorporated relatively easily. However, cost of production is relatively higher than other fabrication methods.
Sources: en.wikipedia.org
After ten minutes, if a yellow-white precipitate is displayed, it is a positive result. If a clear precipitate is displayed, it is a negative result. If a newborn screening was not performed, the result of the newborn screening is a false negative, or the newborn was not treated after a positive result, the clinical findings can be maple syrup odor twelve hours after birth. Four to five days after birth, other signs can present, such as stereotyped movements like "fencing" and "bicycling" along with worsening encephalopathy including lethargy, irregular apnea, and opisthotonus. Seven to ten days after birth, respiratory failure and coma can happen.
August 3 – Allan Nascimento, 34, mixed martial artist (UFC). August 18 – Glória Menezes, 91, actress. September 9 – Jackson Nascimento, 102, football player (Athletico Paranaense, Corinthians) and manager (Athletico Paranaense). September 14 – Aracy Amaral, 96, art historian and curator, director of the Pinacoteca do Estado de São Paulo (1975–1979) and the Museum of Contemporary Art, University of São Paulo (1982–1986). September 15 – Amelinha Teles, 81, journalist and political activist. Paulo César Martin, 62, journalist and radio host (Folha de S.Paulo, TV Globo, Conrad Editora). September 22 – Rick Sollo, 59, singer-songwriter (Rick & Renner) and Sertanejo music producer. September 26 – Pedro Antônio Marchetti Fedalto, 100, Roman Catholic prelate, auxiliary bishop (1966–1970) and archbishop (1970–2004) of Curitiba.
23 May – Sunak confirms that no asylum seekers will be sent to Rwanda before the general election under UK government deportation plans. Nigel Farage, founder of Reform UK, confirms he will not stand as a candidate in the upcoming general election. Police Scotland announces that it has submitted a "standard prosecution report" concerning its investigation into SNP finances to the Crown Office and Procurator Fiscal Service. First Minister of Scotland John Swinney announces he will not accept a parliamentary committee ruling to exclude Michael Matheson from Holyrood for 27 days over his £11,000 iPad charges bill, saying the decision is "prejudiced" due to the involvement of a Conservative MSP who previously made comments about Matheson. 24 May – Sir John Redwood, MP for Wokingham, announces he will not contest the next election. Former Education Secretary Michael Gove announces he will not stand for parliament again at the next election. Junior health minister Andrea Leadsom announces she will not contest the next election. Craig Mackinlay decides he will not contest the new parliamentary seat of Thanet East after what he describes as "36 hours of intense soul searching" following the announcement of the election and his feeling that the work schedule would be too much to deal with while he continues to recover from sepsis. Greg Clark, MP for Tunbridge Wells, announces he will not contest the next general election.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.